Literature DB >> 21233248

Counterpoint: chemosensitivity assays for recurrent ovarian cancer.

Maurie Markman1.   

Abstract

Unfortunately, no reliable evidence-based data have shown any in vitro chemosensitivity assay strategy to be clinically useful in the management of recurrent ovarian cancer, despite frequent use. Several clinical trials have been proposed with the potential to support or refute the relevance of these approaches.

Entities:  

Mesh：

Year:  2011        PMID： 21233248     DOI： 10.6004/jnccn.2011.0010

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  3 in total

1.  Intracellular optical doppler phenotypes of chemosensitivity in human epithelial ovarian cancer.

Authors:  Zhe Li; Ran An; Wendy M Swetzig; Margaux Kanis; Nkechiyere Nwani; John Turek; Daniela Matei; David Nolte
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

2.  Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study.

Authors:  C Tian; D J Sargent; T C Krivak; M A Powell; M J Gabrin; S L Brower; R L Coleman
Journal:  Br J Cancer       Date:  2014-07-08       Impact factor: 7.640

3.  Intracellular Doppler Signatures of Platinum Sensitivity Captured by Biodynamic Profiling in Ovarian Xenografts.

Authors:  Daniel Merrill; Ran An; Hao Sun; Bakhtiyor Yakubov; Daniela Matei; John Turek; David Nolte
Journal:  Sci Rep       Date:  2016-01-06       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.